OXFORD, United Kingdom, Aug. 10, 2023 Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness. -Today at 08:02 am- MarketScreener
Vaccitech plc: Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events in women with low grade human. | April 17, 2023